Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Anixa Biosciences Inc (NASDAQ:ANIX) has received an average rating of "Moderate Buy" from five ratings firms, with a 12-month target price of $9.00.
• Company director Lewis H. Titterton, Jr. recently purchased 10,000 shares at $3.08 per share, increasing his ownership stake to 25.30%.
• Anixa's stock is currently down 2.6% and has a market cap of $137.61 million, with a 52-week trading range between $2.07 and $4.98.

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) has received an average recommendation of "Moderate Buy" from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $9.00.

Several equities research analysts have weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Anixa Biosciences in a report on Tuesday, October 14th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research report on Thursday, September 11th. Zacks Research raised Anixa Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Monday. Finally, D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, October 7th.

Insiders Place Their Bets

In related news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company's stock in a transaction on Thursday, July 31st. The stock was bought at an average price of $3.08 per share, with a total value of $30,800.00. Following the completion of the transaction, the director owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. This represents a 1.06% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 25.30% of the company's stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC acquired a new position in Anixa Biosciences in the first quarter valued at $35,000. Jane Street Group LLC boosted its holdings in Anixa Biosciences by 37.2% in the second quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock valued at $138,000 after acquiring an additional 11,340 shares during the last quarter. Marshall Wace LLP acquired a new position in Anixa Biosciences in the second quarter valued at $39,000. Benjamin Edwards Inc. acquired a new position in Anixa Biosciences in the second quarter valued at $37,000. Finally, NewEdge Advisors LLC acquired a new position in Anixa Biosciences in the second quarter valued at $33,000. Hedge funds and other institutional investors own 29.13% of the company's stock.

Anixa Biosciences Stock Down 2.6%

NASDAQ:ANIX opened at $4.18 on Wednesday. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $4.98. The company has a market capitalization of $137.61 million, a P/E ratio of -11.94 and a beta of 0.69. The stock's fifty day moving average is $3.42 and its two-hundred day moving average is $3.13.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings data on Wednesday, September 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. Sell-side analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.